FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2923013365> ?p ?o ?g. }

• W2923013365 endingPage "1698" @default.
• W2923013365 startingPage "1690" @default.
• W2923013365 abstract "BackgroundWe evaluated perioperative bleeding after coronary artery bypass grafting (CABG) in patients preoperatively treated with ticagrelor or clopidogrel, stratified by discontinuation of these P2Y12 inhibitors.MethodsAll patients from the prospective, European Multicenter Registry on Coronary Artery Bypass Grafting (E-CABG) treated with ticagrelor or clopidogrel undergoing isolated primary CABG were eligible. The primary outcome measure was severe or massive bleeding defined according to the Universal Definition of Perioperative Bleeding, stratified by P2Y12 inhibitor discontinuation. Secondary outcome measures included four additional definitions of major bleeding. Propensity score matching was performed to adjust for differences in preoperative and perioperative covariates.ResultsOf 2,311 patients who were included, 1,293 (55.9%) received clopidogrel and 1,018 (44.1%) ticagrelor preoperatively. Mean time between discontinuation and the operation was 4.5 ± 3.2 days for clopidogrel and 4.9 ± 3.0 days for ticagrelor. In the propensity score–matched cohort, ticagrelor-treated patients had a higher incidence of major bleeding according to Universal Definition of Perioperative Bleeding when ticagrelor was discontinued 0 to 2 days compared with 3 days before the operation (16.0% vs 2.7%, p = 0.003). Clopidogrel-treated patients had a higher incidence of major bleeding according to the Universal Definition of Perioperative Bleeding when clopidogrel was discontinued 0 to 3 days compared with 4 to 5 days before the operation (15.6% vs 8.3%, p = 0.031).ConclusionsIn patients receiving ticagrelor 2 days before CABG and in those receiving clopidogrel 3 days before CABG, there was an increased rate of severe bleeding. Postponing nonemergent CABG for at least 3 days after discontinuation of ticagrelor and 4 days after clopidogrel should be considered. We evaluated perioperative bleeding after coronary artery bypass grafting (CABG) in patients preoperatively treated with ticagrelor or clopidogrel, stratified by discontinuation of these P2Y12 inhibitors. All patients from the prospective, European Multicenter Registry on Coronary Artery Bypass Grafting (E-CABG) treated with ticagrelor or clopidogrel undergoing isolated primary CABG were eligible. The primary outcome measure was severe or massive bleeding defined according to the Universal Definition of Perioperative Bleeding, stratified by P2Y12 inhibitor discontinuation. Secondary outcome measures included four additional definitions of major bleeding. Propensity score matching was performed to adjust for differences in preoperative and perioperative covariates. Of 2,311 patients who were included, 1,293 (55.9%) received clopidogrel and 1,018 (44.1%) ticagrelor preoperatively. Mean time between discontinuation and the operation was 4.5 ± 3.2 days for clopidogrel and 4.9 ± 3.0 days for ticagrelor. In the propensity score–matched cohort, ticagrelor-treated patients had a higher incidence of major bleeding according to Universal Definition of Perioperative Bleeding when ticagrelor was discontinued 0 to 2 days compared with 3 days before the operation (16.0% vs 2.7%, p = 0.003). Clopidogrel-treated patients had a higher incidence of major bleeding according to the Universal Definition of Perioperative Bleeding when clopidogrel was discontinued 0 to 3 days compared with 4 to 5 days before the operation (15.6% vs 8.3%, p = 0.031). In patients receiving ticagrelor 2 days before CABG and in those receiving clopidogrel 3 days before CABG, there was an increased rate of severe bleeding. Postponing nonemergent CABG for at least 3 days after discontinuation of ticagrelor and 4 days after clopidogrel should be considered." @default.
• W2923013365 created "2019-04-01" @default.
• W2923013365 creator A5004893991 @default.
• W2923013365 creator A5006358029 @default.
• W2923013365 creator A5014280780 @default.
• W2923013365 creator A5018310886 @default.
• W2923013365 creator A5026116267 @default.
• W2923013365 creator A5028221136 @default.
• W2923013365 creator A5034573269 @default.
• W2923013365 creator A5040861934 @default.
• W2923013365 creator A5046670203 @default.
• W2923013365 creator A5046691342 @default.
• W2923013365 creator A5052377103 @default.
• W2923013365 creator A5053047084 @default.
• W2923013365 creator A5053221594 @default.
• W2923013365 creator A5053429712 @default.
• W2923013365 creator A5072788055 @default.
• W2923013365 creator A5076242520 @default.
• W2923013365 creator A5077406821 @default.
• W2923013365 creator A5078676861 @default.
• W2923013365 creator A5086893879 @default.
• W2923013365 creator A5088612562 @default.
• W2923013365 creator A5089304120 @default.
• W2923013365 date "2019-06-01" @default.
• W2923013365 modified "2023-10-01" @default.
• W2923013365 title "Bleeding in Patients Treated With Ticagrelor or Clopidogrel Before Coronary Artery Bypass Grafting" @default.
• W2923013365 cites W1554423037 @default.
• W2923013365 cites W2001707768 @default.
• W2923013365 cites W2013204694 @default.
• W2923013365 cites W2064377485 @default.
• W2923013365 cites W2107522704 @default.
• W2923013365 cites W2114879453 @default.
• W2923013365 cites W2122779695 @default.
• W2923013365 cites W2140501627 @default.
• W2923013365 cites W2144845635 @default.
• W2923013365 cites W2156255513 @default.
• W2923013365 cites W2161055506 @default.
• W2923013365 cites W2214085741 @default.
• W2923013365 cites W2266464525 @default.
• W2923013365 cites W2507796525 @default.
• W2923013365 cites W2523442834 @default.
• W2923013365 cites W2752033985 @default.
• W2923013365 cites W2789575341 @default.
• W2923013365 doi "https://doi.org/10.1016/j.athoracsur.2019.01.086" @default.
• W2923013365 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30898561" @default.
• W2923013365 hasPublicationYear "2019" @default.
• W2923013365 type Work @default.
• W2923013365 sameAs 2923013365 @default.
• W2923013365 citedByCount "32" @default.
• W2923013365 countsByYear W29230133652019 @default.
• W2923013365 countsByYear W29230133652020 @default.
• W2923013365 countsByYear W29230133652021 @default.
• W2923013365 countsByYear W29230133652022 @default.
• W2923013365 countsByYear W29230133652023 @default.
• W2923013365 crossrefType "journal-article" @default.
• W2923013365 hasAuthorship W2923013365A5004893991 @default.
• W2923013365 hasAuthorship W2923013365A5006358029 @default.
• W2923013365 hasAuthorship W2923013365A5014280780 @default.
• W2923013365 hasAuthorship W2923013365A5018310886 @default.
• W2923013365 hasAuthorship W2923013365A5026116267 @default.
• W2923013365 hasAuthorship W2923013365A5028221136 @default.
• W2923013365 hasAuthorship W2923013365A5034573269 @default.
• W2923013365 hasAuthorship W2923013365A5040861934 @default.
• W2923013365 hasAuthorship W2923013365A5046670203 @default.
• W2923013365 hasAuthorship W2923013365A5046691342 @default.
• W2923013365 hasAuthorship W2923013365A5052377103 @default.
• W2923013365 hasAuthorship W2923013365A5053047084 @default.
• W2923013365 hasAuthorship W2923013365A5053221594 @default.
• W2923013365 hasAuthorship W2923013365A5053429712 @default.
• W2923013365 hasAuthorship W2923013365A5072788055 @default.
• W2923013365 hasAuthorship W2923013365A5076242520 @default.
• W2923013365 hasAuthorship W2923013365A5077406821 @default.
• W2923013365 hasAuthorship W2923013365A5078676861 @default.
• W2923013365 hasAuthorship W2923013365A5086893879 @default.
• W2923013365 hasAuthorship W2923013365A5088612562 @default.
• W2923013365 hasAuthorship W2923013365A5089304120 @default.
• W2923013365 hasBestOaLocation W29230133651 @default.
• W2923013365 hasConcept C126322002 @default.
• W2923013365 hasConcept C141071460 @default.
• W2923013365 hasConcept C164705383 @default.
• W2923013365 hasConcept C2777849778 @default.
• W2923013365 hasConcept C2778715236 @default.
• W2923013365 hasConcept C2780890252 @default.
• W2923013365 hasConcept C31174226 @default.
• W2923013365 hasConcept C42219234 @default.
• W2923013365 hasConcept C500558357 @default.
• W2923013365 hasConcept C71924100 @default.
• W2923013365 hasConceptScore W2923013365C126322002 @default.
• W2923013365 hasConceptScore W2923013365C141071460 @default.
• W2923013365 hasConceptScore W2923013365C164705383 @default.
• W2923013365 hasConceptScore W2923013365C2777849778 @default.
• W2923013365 hasConceptScore W2923013365C2778715236 @default.
• W2923013365 hasConceptScore W2923013365C2780890252 @default.
• W2923013365 hasConceptScore W2923013365C31174226 @default.
• W2923013365 hasConceptScore W2923013365C42219234 @default.
• W2923013365 hasConceptScore W2923013365C500558357 @default.
• W2923013365 hasConceptScore W2923013365C71924100 @default.
• W2923013365 hasFunder F4320322315 @default.

• next